Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

This was the stock's third consecutive day of losses.

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and ...

Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust ...

Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the ...

Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.3% loss on the day. Meanwhile, the Dow ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.